Cognitive Impairment Assessment in Breast Cancer Survivors (NCT07582770) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Cognitive Impairment Assessment in Breast Cancer Survivors
Italy200 participantsStarted 2026-05
Plain-language summary
This study is a monocentric, observational, cross-sectional study with a case-control design, aimed at evaluating the construct validity, discriminative ability, and diagnostic accuracy of a second-level neuropsychological test battery for the detection of cancer-related cognitive impairment in breast cancer survivors.
Who can participate
Age range
18 Years – 65 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age between 18 and 65 years old
* Patient with a previous documented diagnosis of non-metastatic breast cancer (only for breast cancer survivor gruop)
* Patient has completed chemotherapy for at least 6 months and for a maximum of 36 months if planned (only for breast cancer survivor gruop)
* Understanding of the Italian language and ability to give informed consent
Exclusion Criteria:
* Presence of brain metastases or history of brain radiation therapy (only for breast cancer survivor gruop)
* Patient with previous diagnosis of other malignant tumors in addition to breast cancer (only for breast cancer survivor gruop)
* Patient with a previous diagnosis of malignant carcinomas (only for control gruop)
* Patient with a history of brain damage with unresolved neurological consequences
* Patient with previous or current serious neurological pathologies
* Patient with severe psychiatric conditions
* Patient with systemic pathologies that could interfere with cognitive abilities
* Patient taking medications that have a strong cognitive impact and that have not been stabilized for at least 4 weeks prior to enrollment
* Patient with visual or hearing impairments that are not properly corrected
* Patient with any disability that might compromise the validity of cognitive tests
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Validation of a second-level cognitive test battery to be employed for clinical use for the detection of CRCI in breast cancer survivors